KUALA LUMPUR, Nov 11 (Bernama) — Adagene Inc (Adagene) has announced clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, in two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in Boston.
Acording to a statement, the first poster reviewed data from an open label, phase 1b/2 dose escalation and dose expansion trial evaluating ADG116 as monotherapy and in combination with toripalimab in heavily pre-treated patients with advanced metastatic solid tumours.
The poster is titled “A Phase 1b/2 Study of a Novel Anti-CTLA-4 NEObody™ ADG116 Monotherapy and in Combination with Toripalimab (Tori; Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors”.
Key findings as of the data cutoff date on Sept 19, 2022, include compelling, differentiated safety profile demonstrated with ADG116 monotherapy up to 15 mg/kg; and monotherapy efficacy shown in heavily pre-treated patients.
Meanwhile, findings from a second poster, “A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of an Anti-CTLA-4 NEObody™ ADG116 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors: A Preliminary Update”, established a safe and potentially active dose level for ADG116 in combination with pembrolizumab.
“These data provide compelling clinical evidence for our unique approach to targeting a distinct and highly conserved epitope of CTLA-4 with NEObody ADG116 to achieve enhanced anti-CTLA-4 blockade for both improved efficacy and safety profiles in single agent and combination settings, when combined with two different anti-PD-1 therapies,” said Co-founder, Chief Executive Officer and Chairman of Adagene, Peter Luo, Ph.D.
Adagene Inc is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.
More details at https://investor.adagene.com.
— BERNAMA
wonderland 